Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/05/28 18:04:18」(JST)
wiki en
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 特発性低身長に対する成長ホルモン治療 growth hormone treatment for idiopathic short stature
- 2. 小児における成長ホルモン欠乏症の治療 treatment of growth hormone deficiency in children
- 3. 成長ホルモン不感受性症候群 growth hormone insensitivity syndromes
- 4. 拒食症：内分泌合併症と患者のマネージメント anorexia nervosa endocrine complications and their management
English Journal
- Expression of Recombinant Human Insulin-like Growth Factor Type 1 (rhIGF-1) in Escherichia coli.
- Iranpoor H1, Omidinia E2, Vatankhah V3, Gharanjik V4, Shahbazi M5.
- Avicenna journal of medical biotechnology.Avicenna J Med Biotechnol.2015 Jul-Sep;7(3):101-5.
- BACKGROUND: Human insulin-like growth factor type 1 (hIGF-1) is a protein consisting of 70 amino acids (MW=7.6 kDa) and mainly synthesized by liver. Mecasermin (Trade name INCRELEX) is the synthetic form of the protein which is used as an effective treatment for particular disorders such as short st
- PMID 26306149
- Desensitization to mecasermin in an insulin-like growth factor 1-deficient patient.
- Gutiérrez-Fernández D1, Moreno-Ancillo Á2, Foncubierta-Fernández A3, López-Martínez I4, Lechuga-Sancho A4, Fernández-Anguita MJ5.
- Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.Ann Allergy Asthma Immunol.2015 Jun;114(6):523-5. doi: 10.1016/j.anai.2015.03.004. Epub 2015 Apr 3.
- PMID 25843163
- The insulin-like growth factor I system: physiological and pathophysiological implication in cardiovascular diseases associated with metabolic syndrome.
- Ren J1, Anversa P2.
- Biochemical pharmacology.Biochem Pharmacol.2015 Feb 15;93(4):409-17. doi: 10.1016/j.bcp.2014.12.006. Epub 2014 Dec 23.
- Metabolic syndrome is a cluster of risk factors including obesity, dyslipidemia, hypertension, and insulin resistance. A number of theories have been speculated for the pathogenesis of metabolic syndrome including impaired glucose and lipid metabolism, lipotoxicity, oxidative stress, interrupted neu
- PMID 25541285
Japanese Journal
- 545 組換えメカセルミン(IGF-I)の大量精製
- 日本生物工学会大会講演要旨集 平成8年度, 153, 1996-09-05
- NAID 110002925102
- 544 大腸菌HB101によるメカセルミン(IGF-1)融合蛋白の高生産
- 日本生物工学会大会講演要旨集 平成8年度, 153, 1996-09-05
- NAID 110002925101
- Large Scale Purification of Recombinant Insulin-Like Growth Factor I (IGF-I, Mecasermin) from a Fused Protein Produced in Escherichia coli
- Journal of fermentation and bioengineering 82(2), 134-139, 1996-08-25
- NAID 110002682339
Related Links
- Mecasermin is made by Tercica Pharmaceuticals (Increlex) as a treatment for 'short stature' due to severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies ...
- Mecasermin can cause side effects that may impair thinking, reactions, or physical abilities. The child should avoid driving or doing anything else that requires alertness or coordination for the first 2 or 3 hours after a mecasermin ...
Related Pictures
★リンクテーブル★
| リンク元 | 「メカセルミン」 |
「メカセルミン」
- 英
- mecasermin
- 商
- ソマゾン
- 関
- ソマトメジンC
- ソマトメジンC製剤